Psoriasis is a chronic disease that can affect many areas of the body. The use of topical corticosteroids (TCS) is a common treatment, although long-term safety of TCS remains a concern.
A recent article in Dermatology Times cites a Journal of Drugs in Dermatology study which examines how Topical Halobetsol Propionate 0.01% lotion appears to “safely and quickly improve lower-extremity psoriatic lesions,” over typical TCS treatments.
“A post hoc analysis of data from phase 3 studies investigating the e fficacy of halobetasol propionate 0.01% lotion for treating moderate-to-severe plaque psoriasis showed that the topical corticosteroid was associated with rapid improvement, and findings should help dermatologists with treatment decisions for patients with disease involving leg lesions, said Neal Bhatia, M.D., director of clinical dermatology at Therapeutics Clinical Research, San Diego, and the lead author of the paper.”
At the conclusion of the eight-week treatment, the rate of success was significantly higher for patients randomized to once-daily treatment with halobetasol 0.01% lotion compared with vehicle-treated controls (P<.001 for both comparisons).
View Article Now
You May Also Like
JDD in the News: Ruxolitinib vs. Triamcinolone for Atopic Dermatitis
JDD in the News: Ruxolitinib vs. Triamcinolone for Atopic Dermatitis
MedPage Today/Dermatology World Weekly highlighted a Journal of Drugs in Dermatology study comparing a topical JAK inhibitor with a common topical steroid in atopic dermatitis (AD). The study, “Ruxolitinib Cream…
Management of Nail Toxicities From Fibroblast Growth Factor Receptor Inhibitors
Management of Nail Toxicities From Fibroblast Growth Factor Receptor Inhibitors
Nail Toxicities with FGFR Inhibitors — A JDD Systematic Review Worth Reading Have you read this article from the March 2026 issue of JDD? A systematic review covering reports through…
JDD in the News: Distinguishing Malassezia Folliculitis from Acne Vulgaris
JDD in the News: Distinguishing Malassezia Folliculitis from Acne Vulgaris
Dermatology Times highlighted three Journal of Drugs in Dermatology studies in recent articles, including an examination of “fungal acne.” In the study, “Malassezia Folliculitis Presentation, Diagnosis, and Treatment: A Review…
